Based on the strong associations observed between lactylation risk, PD-L1 expression, TMB, and MSI, it is reasonable to conclude that lactylation risk, including SLC16A7, may have potential as a biomarker for predicting the response to immunotherapy in gastric cancer. The gene discussed is CD274; the disease is gastric cancer.